Navigation Links
Efficacy of OrbusNeich's Genous Bio-Engineered R Stent Compares,Favorably to Drug-Eluting Stents

Risk of Late Thrombosis is Minimized with Genous Stent

BARCELONA, Spain, May 23, 2007 /PRNewswire/ -- The efficacy of OrbusNeich's Genous(TM) Bio-engineered R stent compares favorably to that of drug-eluting stents, while the risk of late thrombosis is minimized with the Genous stent, according to an interim analysis of post-marketing data presented today by Robbert de Winter, M.D., Ph.D., at EuroPCR 2007 in Barcelona, Spain.

Collected from more than 120 sites in 29 countries, follow-up data for patients who received at least one Genous Bio-engineered R stent show:

    -- For 2,175 patients at 30 days, the target lesion revascularization

       (TLR) rate was 0.05%, the major adverse cardiac events (MACE) rate was

       1.61%, and the sub-acute thrombosis (SAT) rate was 0.37%


    -- For 1,039 patients at six months, the TLR rate was 2.89%, the MACE rate

       was 5.87%, and the thrombosis rate was 0.88%

"The real-world data speak to the promise of OrbusNeich's innovative pro- healing approach with Genous, especially when we compare the findings to those of the drug-eluting stent registries," said de Winter, a co-principal investigator of the study and director of the catheterization laboratory at the Academic Medical Center in Amsterdam. "The importance of this interim data is that Genous appears to be as effective as drug-eluting stents with only the need for minimal dual-antiplatelet therapy, which is safer for patients and less expensive."

OrbusNeich's e-HEALING is a multi-center, worldwide prospective registry of patients treated with the Genous Bio-engineered R stent in accordance with the instructions for use. The protocol recommends that patients receive two weeks of statin treatment prior to the procedure and one month of clopidogrel treatment after the procedure. Clinical follow-up takes place at 30 days, six months and 12 months. The primary outcome of the reg
'"/>




Page: 1 2 3

Related medicine technology :

1. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
6. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
7. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
8. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
9. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
10. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
11. Studies Show Efficacy and Safety of Alexions Soliris in Broad Population of PNH Patients
Post Your Comments:
(Date:8/29/2014)... , Aug. 29, 2014 Pomerantz LLP ... S.A. ("EDAP" or the "Company") (NASDAQ: EDAP ) ... in United States District Court, Southern District of ... is on behalf of a class consisting of all ... 1, 2013 and July 30, 2014, inclusive (the "Class ...
(Date:8/29/2014)... , Aug. 29, 2014   Mast ... biopharmaceutical company, announced today that Santosh Vetticaden, Chief ... leaving the Company, for personal reasons, in mid-September.  ... Medical Officer of Aires Pharmaceuticals, which Mast acquired ... responsibilities as the Company,s interim Chief Medical Officer.  ...
(Date:8/29/2014)... PLEASANTON, Calif. , Aug. 29, 2014 ... leader in device-based mechanical circulatory support therapies to save, ... be participating in the 2014 Morgan Stanley Global Healthcare ... F. Burbach , President and Chief Executive Officer, will ... p.m., Eastern Daylight Time (9:55 a.m., Pacific Daylight Time). ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4
... Inc. (NYSE: PFE ) today announced ... Innovation, an entrepreneurial network of partnerships with leading ... by accessing leading translational researchers.  The University of ... the network. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) ...
... 16, 2010 Baxa Corporation , a leading ... operations, today announced significant upgrades to its DoseEdge ... workflow management tool that verifies the use of correct ... chemo, TPN and oral liquid doses.  This release includes ...
Cached Medicine Technology:Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco 2Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco 3Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco 4Baxa Releases Upgrade for DoseEdge™ - the Only Dose Management System With Comprehensive Formulary Management Functionality 2Baxa Releases Upgrade for DoseEdge™ - the Only Dose Management System With Comprehensive Formulary Management Functionality 3Baxa Releases Upgrade for DoseEdge™ - the Only Dose Management System With Comprehensive Formulary Management Functionality 4
(Date:8/29/2014)... The Department of Health and Human Services (HHS) ... today allowing healthcare providers to attest for Meaningful Use ... (CEHRT) or a combination of the 2011 and 2014 ... able to fully implement 2014 Edition CEHRT for a ... use 2011 Edition CEHRT, or a combination of 2011/2014 ...
(Date:8/29/2014)... Los Angeles, CA (PRWEB) August 29, 2014 ... has announced his plan to rename his practice to ... US Hair Restoration has served the needs of hair ... clients who traveled to its centers in Los Angeles, ... results through surgical and non surgical treatments, many of ...
(Date:8/29/2014)... 30, 2014 UWDress.com, one of the ... its latest collection of 2014 floor length bridesmaid ... for these wonderful items. According to the company’s marketing ... a greatly discounted rate (up to 60 percent off) ... products has a special neckline: strapless, one-shoulder, bateau and ...
(Date:8/29/2014)... 2014 As reported by GantDaily.com in the ... Abuse Trends , Outbreaks (8/20), the National Institute on Drug ... drug abuse trends by turning to social media. As NIDA ... it is also working with the University of Maryland to ... Warning System, which will be funded by the National Institute ...
(Date:8/29/2014)... Dallas, Texas (PRWEB) August 30, 2014 ... Glass microfiber Industry, 2009-2019 is a professional and ... microfiber industry. The report firstly reviews the basic ... and manufacturing technology. The report then explores global ... their product specification, capacity, Production value, and market ...
Breaking Medicine News(10 mins):Health News:Quirk Healthcare Outlook on MU2 Delay Confirmation 2Health News:US Hair Restoration Changes Name to Parsa Mohebi Hair Restoration to Better Reflect Founder 2Health News:2014 Floor Length Bridesmaid Dresses for Sale at UWDress.com 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4
... Based on findings of a recent study researchers say eating ... Researchers say they have found a correlation between high consumption ... hot dogs, and lunch meats like ham, salami and bologna, ... study, nearly 149,000 meat eaters between ages 50 and 74 ...
... part of the body’s immune system and help protect ... A new study shows promising treatment for acute myelogenous ... natural killer cells from a patient’s family member. ... the highly fatal cancer of the bone marrow that ...
... study researchers say autistic boys with language problems might have ... disorder known as Specific Language Impairment (SLI) // and they ... and how to choose the best treatments for individual components ... at Broca’s area -- a key language center in the ...
... as a man’s disease, but recent reports suggest it ... is helping to identify which women are at highest ... records of nearly 2,400 women taking part in the ... heart disease are about three-times more likely to develop ...
... New research shows that people who have implanted ... safely use magnetic resonance imaging .// ,Pacemakers ... regulate an abnormal heartbeat known as arrhythmia. Researchers ... of the MRI may heat up metal components ...
... gene known as “mighty mouse” might be beneficial in ... a German neurologist , stumbled // on a newborn who ... child had a mutation in his myostatin gene that effectively ... known to regulate muscle growth. So far the child, now ...
Cached Medicine News:
For the quantitative determination of direct bilirubin in human serum. Linearity: 20 mg/dl...
Intended for the quantitative determination of direct bilirubin in serum. Modified EvelynMalloy Method. Endpoint Reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... is the first microplate spectrophotometer designed specifically ... days per week. With rugged hardware, proven ... breaks the barrier of traditional spectrophotometry to ... instrument can easily read up to eight, ...
... microplate spectrophotometer designed specifically to run 24 ... With rugged hardware, proven optical performance and ... of traditional spectrophotometry to obtain results quickly, ... read up to eight, 1 cm Biocell ...
Medicine Products: